Japan Approves Astellas Transplant Drug Delayed In U.S.
This article was originally published in PharmAsia News
Astellas Pharma said it has won approval to market its Graceptor (tacrolimus) transplant drug in Japan. The new version is a once-daily form of Astellas' twice-daily Prograf, a $2 billion-a-year seller for the company, but one that lost its U.S. patent protection earlier this year. The U.S. FDA has yet to approve tacrolimus as a treatment for kidney and liver transplants, issuing "approvable" letters on the grounds Astellas submitted insufficient data. The U.S. agency also has declined approval for a heart transplant indication, issuing a "non approvable" letter. Tacrolimus already is approved in Europe, where it is marketed as Advagraf. (Click here for more
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.